On 17-09-2020 (Thursday), Shares of Zynerba Pharmaceuticals, Inc., (NASDAQ: ZYNE) displayed a change of 7.65 after which it closed the day’ session at $3.8. The volume amounted to 2835728 shares which compares with the average volume of 1.37M shares. Zynerba Pharmaceuticals, Inc., a USA based Company, belongs to Healthcare sector and Drug Manufacturers – Specialty & Generic industry. The shares of Zynerba Pharmaceuticals, Inc. was among the active stocks of the last trading sessions.
To clear the blur picture shareholders will need to look a little deeper. The LiveRamp Holdings, Inc. has shown a weekly performance of 8.26% and monthly performance stands at -1.81%.
The stock has shown a quarterly performance of -40.9% and a half-year performance stands at 22.58%. Analyst recommendation for this stock stands at -37.09.
The stock price moved with change of 0.1875 to its 50 Day low point and changed -0.1264 comparing to its 50 Day high point.
Looking into the profitability ratios of ZYNE stock, the investor will find its ROE, ROA, ROI standing at -60.2%, -52.4% and 0%, respectively. The current relative strength index (RSI) reading is 56.12.
Target Price ZYNE:
Target Price informs the investors, a stock survey at which a trader is willing to buy or sell a stock. Target pricing at which a trader projects that a buyer will buy a product. Analyst’s mean target price for the company is $0.
The stock price volatility remained at 5.62 in recent month and reaches at 7.17 for the week. The Average True Range (ATR) is also a measure of volatility is currently sitting at 0.22.
Simple Moving Averages ZYNE:
The moving average is easy to calculate and once plotted on a chart, is a powerful visual trend-spotting tool. In theory, there is an infinite number of simple moving averages but the most common are three SMA20, SMA50 and SMA200. SMA20 is the last stop on the bus for short-term traders. Its distance from 20-days simple moving average is 3.13% and its distance from 50-days simple moving average is 1.59% while it has a distance of -16.58% from the 200-days simple moving average.
Most Important details of Zynerba Pharmaceuticals, Inc. (EPS):
EPS in next five year years is expected to touch -17.8% while EPS growth in past 5 year was -17.8% along with sales growth of % in the last five years. EPS growth in next year is estimated to reach 42.6% while EPS growth estimate for this year is set at 42.6%.